Facts and controversies in the use of trastuzumab in the adjuvant setting
The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
The human epidermal growth factor receptor-2 (HER2) is overexpressed and/or amplified in up to 25% of breast cancer patients, and this feature is associated with an aggressive phenotype, high recurrence rate and reduced survival. Until recently, combination chemotherapy (with or without endocrine therapy) was the only effective adjuvant treatment for HER2-positive patients. Trastuzumab is a monoclonal antibody directed against the HER2 extracellular domain, and five recent adjuvant breast cancer trials have demonstrated an astonishing and highly reproducible benefit in halving the recurrence rate and reducing mortality in patients with this phenotype. Many questions related to trastuzumab use in the adjuvant setting still remain; these include the optimum timing and duration of treatment, trastuzumab use with taxanes and radiotherapy, its role in small node-negative tumors, the optimum chemotherapy regimens and cost-effectiveness. This Review outlines the five adjuvant trastuzumab studies and discusses the controversies and challenges that have emerged for both the clinician and healthcare authorities worldwide as a consequence of the results from these trials.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Measuring HER2 status using cfDNA offers considerable potential as a diagnostic and prognostic test (19,30,31).”
From Comparison of microfluidic digital PCR and conventional quantitative PCR for measuring copy number variation (2012) · cites this paper as [30]
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760 · cited 1×
“dtd" [ ]> Introduction Up to 25% of women with early-stage breast cancer have tumors that are positive for expression of the human epidermal growth factor receptor-2 (HER2), and these tumors are associated with an aggressive phenotype, a high recurrence rate and reduced survival”
BackgroundSlamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · cited 1×
“Trastuzumab (Herceptin ® ; Genentech, South San Francisco, CA), a monoclonal antibody directed against the extracellular domain of the HER2 receptor, has been tested in HER2-positive patients with early-stage breast cancer, after demonstrating significant benefit in the metastatic setting”
BackgroundStudies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.022 · Cited by 1,858 · cited 1×
“increased signaling from other HER receptors; PTEN (phosphatase and tensin homolog) inactivation or loss resulting in increased Akt activity”
BackgroundMarty, M., Cognetti, F., Maraninchi, D., Snyder, R., Mauriac, L., Tubiana-Hulin, M., Chan, S., Grimes, D., Antón, A., Lluch, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.173 · Cited by 1,597
Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience
Seidman, A. D., Hudis, C. A., Pierri, M. K., Shak, S., Paton, V. E., Ashby, M. A., Murphy, M., Stewart, S. J., & Keefe, D. L. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.5.1215 · Cited by 1,563
Smith, I., Procter, M., Gelber, R. D., Guillaume, S., Feyereislova, A., Dowsett, M., Goldhirsch, A., Untch, M., Mariani, G., Baselga, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60028-2 · Cited by 1,507
Research works printed but not linked: 2
- Slamon D et al. (2006) BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC-T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients. Breast Cancer Res Treat 100: S2
- Mackey JR et al. (2006) Trastuzumab prolongs progression-free survival in hormone-dependent and HER-2 positive metastatic breast cancer. Presented at the San Antonio Breast Cancer Symposium. 2006 December 14–17 [ http://www.abstracts2view.com/sabcs06/view.php?nu=SABCS06L_665 ]
Cited by
Ross, J. S., Slodkowska, E. A., Symmans, W. F., Pusztai, L., Ravdin, P. M., & Hortobagyi, G. N. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0230 · Cited by 1,144
Whale, A. S., Huggett, J. F., Cowen, S., Speirs, V., Shaw, J., Ellison, S., Foy, C. A., & Scott, D. J. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks203 · Cited by 453
“The power calculations described in this publication are based on a one-tailed test as we were interested detecting HER2 amplification (where lt> lr) which has clinical and prognostic relevance (30,31).”
MethodTherapeutic Implications of the Cancer Stem Cell Hypothesis
Diehn, M., Cho, R. W., & Clarke, M. F. (2009) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2008.11.002 · Cited by 139
Is There a Role for Circulating Tumor Cells in the Management of Breast Cancer?
Hayes, D. F., & Smerage, J. B. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4481 · Cited by 109
Metabolic control analysis indicates a change of strategy in the treatment of cancer
Moreno‐Sánchez, R., Saavedra, E., Rodríguez‐Enríquez, S., Gallardo‐Pérez, J. C., Quezada, H., & Westerhoff, H. V. (2010) · Mitochondrion · doi:10.1016/j.mito.2010.06.002 · Cited by 83
Metadata
- Authors
- Dinh, P., de Azambuja, E., Cardoso, F., & Piccart-Gebhart, M. J.
- Affiliations
- Institut Jules Bordet (BE)
- ORCID
- Dinh, Phuong
- Venue
- Nature Clinical Practice Oncology
- Published
- 2008-09-09
- Volume
- 5
- Issue
- 11
- Pages
- 645-654
- ISSN
- 1743-4254 (ISSN-L)
- 1743-4262
- OpenAlex
- W1966520215
- Cited by
- 19
- References
- 52
- Citations by year
- 2023: 1 · 2014: 1 · 2013: 1 · 2012: 1
- FWCI
- 0.47
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Clinical Practice Oncology (publishedVersion)
- PubMed (publishedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Keywords
- trastuzumab, HER2-positive breast cancer, adjuvant therapy, HER2 overexpression, taxanes, radiotherapy, node-negative breast cancer, cost-effectiveness, recurrence rate, mortality
- MeSH terms
- Trastuzumab, Antibodies, Monoclonal, Antineoplastic Agents, Belgium, Breast Neoplasms, Clinical Trials as Topic, Cost-Benefit Analysis, Female, Humans, Neoplasm Recurrence, Local, Phenotype, Biomarkers, Tumor, Survival Analysis, Treatment Outcome, Chemotherapy, Adjuvant, Risk Assessment, Erb-b2 Receptor Tyrosine Kinases, Receptor, ErbB-2, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Facts and controversies in the use of trastuzumab in the adjuvant setting. https://app.cochat.ai/papers/10.1038/ncponc1219
- The paper
- Dinh, P., de Azambuja, E., Cardoso, F., & Piccart-Gebhart, M. J. (2008). Facts and controversies in the use of trastuzumab in the adjuvant setting. Nature Clinical Practice Oncology. https://doi.org/10.1038/ncponc1219
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.